Emsam Anti-Depressant Patch NDA Resubmission On Track For 2003 – Mylan
Executive Summary
Mylan Laboratories hopes for FDA approval of the transdermal selegiline product Emsam by mid 2004, Mylan Vice Chairman Robert Coury said during a July 25 conference call